ERAMET (ER7.DE) Fundamental Analysis & Valuation

FRA:ER7 • FR0000131757

Current stock price

50.35 EUR
-1.65 (-3.17%)
Last:

This ER7.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ER7.DE Profitability Analysis

1.1 Basic Checks

  • In the past year ER7 has reported negative net income.
  • ER7 had a negative operating cash flow in the past year.
  • Of the past 5 years ER7 4 years were profitable.
  • Of the past 5 years ER7 4 years had a positive operating cash flow.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • With a Return On Assets value of -1.58%, ER7 is not doing good in the industry: 71.05% of the companies in the same industry are doing better.
  • The Return On Equity of ER7 (-9.29%) is worse than 76.32% of its industry peers.
  • ER7's Return On Invested Capital of 0.80% is on the low side compared to the rest of the industry. ER7 is outperformed by 63.16% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ER7 is in line with the industry average of 8.97%.
  • The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(0.80%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROIC 0.8%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

  • ER7's Profit Margin has declined in the last couple of years.
  • With a Operating Margin value of 1.91%, ER7 is not doing good in the industry: 60.53% of the companies in the same industry are doing better.
  • In the last couple of years the Operating Margin of ER7 has declined.
  • ER7 has a better Gross Margin (68.15%) than 94.74% of its industry peers.
  • ER7's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.91%
PM (TTM) N/A
GM 68.15%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ER7.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ER7 is destroying value.
  • The number of shares outstanding for ER7 has been increased compared to 1 year ago.
  • ER7 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ER7 has an improved debt to assets ratio.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • ER7 has an Altman-Z score of 1.07. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.07, ER7 is not doing good in the industry: 78.95% of the companies in the same industry are doing better.
  • ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
  • ER7 has a worse Debt to Equity ratio (2.03) than 92.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACC0.09
WACC9.17%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
  • ER7's Current ratio of 1.54 is on the low side compared to the rest of the industry. ER7 is outperformed by 68.42% of its industry peers.
  • A Quick Ratio of 1.06 indicates that ER7 should not have too much problems paying its short term obligations.
  • ER7's Quick ratio of 1.06 is in line compared to the rest of the industry. ER7 outperforms 44.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.06
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ER7.DE Growth Analysis

3.1 Past

  • The earnings per share for ER7 have decreased strongly by -219.63% in the last year.
  • ER7 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -64.00% yearly.
  • Looking at the last year, ER7 shows a decrease in Revenue. The Revenue has decreased by -6.91% in the last year.
  • The Revenue has been decreasing by -4.39% on average over the past years.
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%

3.2 Future

  • Based on estimates for the next years, ER7 will show a very negative growth in Earnings Per Share. The EPS will decrease by -55.03% on average per year.
  • The Revenue is expected to grow by 3.35% on average over the next years.
EPS Next Y-333.81%
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%
EPS Next 5Y-55.03%
Revenue Next Year4.29%
Revenue Next 2Y3.55%
Revenue Next 3Y4.96%
Revenue Next 5Y3.35%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. ER7.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ER7. In the last year negative earnings were reported.
  • ER7 is valuated quite expensively with a Price/Forward Earnings ratio of 55.29.
  • Based on the Price/Forward Earnings ratio, ER7 is valued a bit more expensive than 73.68% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ER7 to the average of the S&P500 Index (23.05), we can say ER7 is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 55.29
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • ER7's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.39
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

  • ER7's earnings are expected to decrease with -6.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ER7.DE Dividend Analysis

5.1 Amount

  • No dividends for ER7!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ER7.DE Fundamentals: All Metrics, Ratios and Statistics

ERAMET

FRA:ER7 (4/2/2026, 7:00:00 PM)

50.35

-1.65 (-3.17%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)02-18
Earnings (Next)04-23
Inst Owners14.01%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.45B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts78
Price Target61.41 (21.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 55.29
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 2.68
EV/EBITDA 14.39
EPS(TTM)-3.42
EYN/A
EPS(NY)0.91
Fwd EY1.81%
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROCE 1.16%
ROIC 0.8%
ROICexc 0.95%
ROICexgc 1.09%
OM 1.91%
PM (TTM) N/A
GM 68.15%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Debt/EBITDA 10.29
Cap/Depr 403.31%
Cap/Sales 21.11%
Interest Coverage 0.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.06
Altman-Z 1.07
F-Score2
WACC9.17%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-333.81%
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%
EPS Next 5Y-55.03%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year4.29%
Revenue Next 2Y3.55%
Revenue Next 3Y4.96%
Revenue Next 5Y3.35%
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year-4.34%
EBIT Next 3Y30.08%
EBIT Next 5Y23.12%
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ER7.DE Fundamental Analysis FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.


What is the valuation status of ERAMET (ER7.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.


How profitable is ERAMET (ER7.DE) stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.


How financially healthy is ERAMET?

The financial health rating of ERAMET (ER7.DE) is 2 / 10.


What is the earnings growth outlook for ERAMET?

The Earnings per Share (EPS) of ERAMET (ER7.DE) is expected to decline by -333.81% in the next year.